Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Compass Therapeutics (CMPX) FCF Margin (2024)

Compass Therapeutics' FCF Margin history spans 1 years, with the latest figure at 1265.18% for Q2 2024.

  • On a quarterly basis, FCF Margin changed N/A to 1265.18% in Q2 2024 year-over-year; TTM through Jun 2025 was 5331.18%, a 27976.0% decrease, with the full-year FY2024 number at 5282.24%, changed N/A from a year prior.
  • FCF Margin hit 1265.18% in Q2 2024 for Compass Therapeutics.
  • Over the last five years, FCF Margin for CMPX hit a ceiling of 1265.18% in Q2 2024 and a floor of 1265.18% in Q2 2024.